What is the Eli Lilly and Company stock price forecast?

Eli Lilly and Company is currently trading at $1122.50. View real-time AI analysis on Alpha Lenz.

What is Eli Lilly and Company insider trading activity?

View the latest insider trading data for Eli Lilly and Company on Alpha Lenz.

What is Eli Lilly and Company's P/E ratio?

Eli Lilly and Company's P/E ratio is 48.7.

Eli Lilly and Company

NYSE · LLY

$1.12K-6.85(-0.61%)Pre-market

Ask about Eli Lilly and Company's future dividend policy...

Alpha Chat Insight

“Eli Lilly and Company trades at a P/E of 48.7 (premium valuation) with strong ROE of 101.4%. 3Y revenue CAGR of 31.7% highlights clear growth momentum.”

Ask for details →

Company Overview

Eli Lilly and Company is a leading pharmaceutical firm with a global reputation for developing and marketing innovative medicines. Founded in 1876 and headquartered in Indianapolis, Indiana, the company operates within the pharmaceuticals and biotechnology sector, addressing a wide spectrum of diseases through prescription drugs and biopharmaceutical products. Eli Lilly’s research and development efforts have produced treatments in areas such as oncology, endocrinology (notably diabetes care), immunology, neuroscience, and rare diseases, making it a key player in improving patient outcomes across multiple therapeutic segments. The company's large scale is reflected in its substantial market capitalization, its listing on major exchanges, and its presence in over 120 countries. Eli Lilly’s continued investment in clinical research and strategic collaborations underscores its pivotal role in driving advancements within the pharmaceutical industry, impacting both healthcare systems and patients worldwide.

CEOMr. David A. Ricks

Websitehttps://www.lilly.com

SectorHealthcare

IndustryDrug Manufacturers - General

Employees47,000

Company Statistics

FY 2025

Profile

$1,004.41BMarket Cap

$65.18BRevenue

0.00Shares Out

47,000Employees

Margins

83.04%Gross

53.83%EBITDA

45.56%Operating

39.48%Pre-Tax

31.67%Net

Valuation

48.66P/E

37.85P/B

15.41EV/Sales

29.63EV/EBITDA

168.41P/FCF

Growth (CAGR)

31.69%Rev 3Yr

21.58%Rev 5Yr

50.84%Op Inc 3Yr

33.13%Op Inc 5Yr

48.96%Net Inc 3Yr

27.22%Net Inc 5Yr

Returns

21.59%ROA

101.36%ROE

31.06%ROIC

Financial Health

$7.27BCash & Cash Equivalents

$78.67BNet Debt

323.88%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Eli Lilly and Company trades at a P/E of 48.7 (premium valuation) with strong ROE of 101.4%. 3Y revenue CAGR of 31.7% highlights clear growth momentum.”

Ask for details →

Frequently Asked Questions

Eli Lilly and Company (ticker: LLY) is a company listed on NYSE in the Healthcare sector (Drug Manufacturers - General). It has approximately 47,000 employees. Market cap is $1.0T.

The current price is $1,122.5 with a P/E ratio of 48.66x and P/B of 37.85x.

ROE is 101.36% and operating margin is 45.56%. Annual revenue is $65.2B.